Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases

Carlo C. Quattrocchi, Paola Dell'Aia, Yuri Errante, Filomena Occhicone, Daniela Longo, Vladimir Virzi, Giuseppe Tonini, Nicola Napoli, Daniele Santini, Bruno Beomonte Zobel

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate bone density changes at the level of normal bone and bone metastases after zoledronic acid (ZA) treatment in oncologic patients. Materials and methods: We retrospectively evaluated 72 consecutive adult patients with histologically confirmed solid tumors with at least 1 newly diagnosed bone metastatic lesion. Bone metastases were diagnosed by bone scans and confirmed with computed tomography (CT). Patients received intravenous ZA, 4 mg, by 15-min infusion every 28 day through a peripheral or a central venous access and were monitored for at least 3 months and a maximum of 24 months. Bone density was determined at the level of bone metastases and at the level of normal trabecular and cortical bone using a ROI-based approach. Results: A significant increase was demonstrated at the level of normal trabecular bone of the calvarium and the femoral neck. No significant increase of density was observed at the level of the normal cortical bone. Bone metastases showed a significant increase in CT density as compared to baseline up to 24 months after zoledronic acid. Conclusion: We have found that long term treatment with ZA increases trabecular bone density in oncologic patients whereas normal cortical bone changes are not detectable.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalJournal of Bone Oncology
Volume1
Issue number1
DOIs
Publication statusPublished - Jun 2012

Fingerprint

zoledronic acid
Bone Density
Neoplasm Metastasis
Bone and Bones
Tomography
Femur Neck
Skull
Cancellous Bone
Cortical Bone

Keywords

  • Bone metastasis
  • Cortical bone
  • CT Density
  • Osteolytic
  • Trabecular bone
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology

Cite this

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. / Quattrocchi, Carlo C.; Dell'Aia, Paola; Errante, Yuri; Occhicone, Filomena; Longo, Daniela; Virzi, Vladimir; Tonini, Giuseppe; Napoli, Nicola; Santini, Daniele; Zobel, Bruno Beomonte.

In: Journal of Bone Oncology, Vol. 1, No. 1, 06.2012, p. 24-29.

Research output: Contribution to journalArticle

Quattrocchi, CC, Dell'Aia, P, Errante, Y, Occhicone, F, Longo, D, Virzi, V, Tonini, G, Napoli, N, Santini, D & Zobel, BB 2012, 'Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases', Journal of Bone Oncology, vol. 1, no. 1, pp. 24-29. https://doi.org/10.1016/j.jbo.2012.02.001
Quattrocchi, Carlo C. ; Dell'Aia, Paola ; Errante, Yuri ; Occhicone, Filomena ; Longo, Daniela ; Virzi, Vladimir ; Tonini, Giuseppe ; Napoli, Nicola ; Santini, Daniele ; Zobel, Bruno Beomonte. / Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. In: Journal of Bone Oncology. 2012 ; Vol. 1, No. 1. pp. 24-29.
@article{fa649ea97d194caa861ef790f0c9ec00,
title = "Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases",
abstract = "Purpose: To evaluate bone density changes at the level of normal bone and bone metastases after zoledronic acid (ZA) treatment in oncologic patients. Materials and methods: We retrospectively evaluated 72 consecutive adult patients with histologically confirmed solid tumors with at least 1 newly diagnosed bone metastatic lesion. Bone metastases were diagnosed by bone scans and confirmed with computed tomography (CT). Patients received intravenous ZA, 4 mg, by 15-min infusion every 28 day through a peripheral or a central venous access and were monitored for at least 3 months and a maximum of 24 months. Bone density was determined at the level of bone metastases and at the level of normal trabecular and cortical bone using a ROI-based approach. Results: A significant increase was demonstrated at the level of normal trabecular bone of the calvarium and the femoral neck. No significant increase of density was observed at the level of the normal cortical bone. Bone metastases showed a significant increase in CT density as compared to baseline up to 24 months after zoledronic acid. Conclusion: We have found that long term treatment with ZA increases trabecular bone density in oncologic patients whereas normal cortical bone changes are not detectable.",
keywords = "Bone metastasis, Cortical bone, CT Density, Osteolytic, Trabecular bone, Zoledronic acid",
author = "Quattrocchi, {Carlo C.} and Paola Dell'Aia and Yuri Errante and Filomena Occhicone and Daniela Longo and Vladimir Virzi and Giuseppe Tonini and Nicola Napoli and Daniele Santini and Zobel, {Bruno Beomonte}",
year = "2012",
month = "6",
doi = "10.1016/j.jbo.2012.02.001",
language = "English",
volume = "1",
pages = "24--29",
journal = "Journal of Bone Oncology",
issn = "2212-1374",
publisher = "Elsevier GmbH",
number = "1",

}

TY - JOUR

T1 - Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases

AU - Quattrocchi, Carlo C.

AU - Dell'Aia, Paola

AU - Errante, Yuri

AU - Occhicone, Filomena

AU - Longo, Daniela

AU - Virzi, Vladimir

AU - Tonini, Giuseppe

AU - Napoli, Nicola

AU - Santini, Daniele

AU - Zobel, Bruno Beomonte

PY - 2012/6

Y1 - 2012/6

N2 - Purpose: To evaluate bone density changes at the level of normal bone and bone metastases after zoledronic acid (ZA) treatment in oncologic patients. Materials and methods: We retrospectively evaluated 72 consecutive adult patients with histologically confirmed solid tumors with at least 1 newly diagnosed bone metastatic lesion. Bone metastases were diagnosed by bone scans and confirmed with computed tomography (CT). Patients received intravenous ZA, 4 mg, by 15-min infusion every 28 day through a peripheral or a central venous access and were monitored for at least 3 months and a maximum of 24 months. Bone density was determined at the level of bone metastases and at the level of normal trabecular and cortical bone using a ROI-based approach. Results: A significant increase was demonstrated at the level of normal trabecular bone of the calvarium and the femoral neck. No significant increase of density was observed at the level of the normal cortical bone. Bone metastases showed a significant increase in CT density as compared to baseline up to 24 months after zoledronic acid. Conclusion: We have found that long term treatment with ZA increases trabecular bone density in oncologic patients whereas normal cortical bone changes are not detectable.

AB - Purpose: To evaluate bone density changes at the level of normal bone and bone metastases after zoledronic acid (ZA) treatment in oncologic patients. Materials and methods: We retrospectively evaluated 72 consecutive adult patients with histologically confirmed solid tumors with at least 1 newly diagnosed bone metastatic lesion. Bone metastases were diagnosed by bone scans and confirmed with computed tomography (CT). Patients received intravenous ZA, 4 mg, by 15-min infusion every 28 day through a peripheral or a central venous access and were monitored for at least 3 months and a maximum of 24 months. Bone density was determined at the level of bone metastases and at the level of normal trabecular and cortical bone using a ROI-based approach. Results: A significant increase was demonstrated at the level of normal trabecular bone of the calvarium and the femoral neck. No significant increase of density was observed at the level of the normal cortical bone. Bone metastases showed a significant increase in CT density as compared to baseline up to 24 months after zoledronic acid. Conclusion: We have found that long term treatment with ZA increases trabecular bone density in oncologic patients whereas normal cortical bone changes are not detectable.

KW - Bone metastasis

KW - Cortical bone

KW - CT Density

KW - Osteolytic

KW - Trabecular bone

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84864251542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864251542&partnerID=8YFLogxK

U2 - 10.1016/j.jbo.2012.02.001

DO - 10.1016/j.jbo.2012.02.001

M3 - Article

AN - SCOPUS:84864251542

VL - 1

SP - 24

EP - 29

JO - Journal of Bone Oncology

JF - Journal of Bone Oncology

SN - 2212-1374

IS - 1

ER -